These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18633105)

  • 21. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.
    Villanueva ME; Muñoz AS; Casasola CC; Africa JB; Danguilan RA; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2222-5. PubMed ID: 18790198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Kupin W; Rosen A; Cordovilla T; Tueros L; Herrada E; Miller J
    Clin Transplant; 2008; 22(2):200-10. PubMed ID: 18339140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.
    Barth RN; Janus CA; Lillesand CA; Radke NA; Pirsch JD; Becker BN; Fernandez LA; Thomas Chin L; Becker YT; Odorico JS; D'Alessandro AM; Sollinger HW; Knechtle SJ
    Transpl Int; 2006 Nov; 19(11):885-92. PubMed ID: 17018123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.
    Margreiter R; Klempnauer J; Neuhaus P; Muehlbacher F; Boesmueller C; Calne RY
    Am J Transplant; 2008 Jul; 8(7):1480-5. PubMed ID: 18510632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial.
    Welberry Smith MP; Cherukuri A; Newstead CG; Lewington AJ; Ahmad N; Menon K; Pollard SG; Prasad P; Tibble S; Giddings E; Baker RJ
    Transplantation; 2013 Dec; 96(12):1082-8. PubMed ID: 24056618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Campath induction for kidney transplantation: report of 297 cases.
    Ortiz J; Palma-Vargas J; Wright F; Bingaman A; Agha I; Rosenblatt S; Foster P
    Transplantation; 2008 Jun; 85(11):1550-6. PubMed ID: 18551058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience.
    Froud T; Ricordi C; Baidal DA; Hafiz MM; Ponte G; Cure P; Pileggi A; Poggioli R; Ichii H; Khan A; Ferreira JV; Pugliese A; Esquenazi VV; Kenyon NS; Alejandro R
    Am J Transplant; 2005 Aug; 5(8):2037-46. PubMed ID: 15996257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
    Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial.
    Chan K; Taube D; Roufosse C; Cook T; Brookes P; Goodall D; Galliford J; Cairns T; Dorling A; Duncan N; Hakim N; Palmer A; Papalois V; Warrens AN; Willicombe M; McLean AG
    Transplantation; 2011 Oct; 92(7):774-80. PubMed ID: 21836540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.
    Posselt AM; Bellin MD; Tavakol M; Szot GL; Frassetto LA; Masharani U; Kerlan RK; Fong L; Vincenti FG; Hering BJ; Bluestone JA; Stock PG
    Am J Transplant; 2010 Aug; 10(8):1870-80. PubMed ID: 20659093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.
    Flechner SM; Friend PJ; Brockmann J; Ismail HR; Zilvetti M; Goldfarb D; Modlin C; Mastroianni B; Savas K; Devaney A; Simmonds M; Cook DJ
    Am J Transplant; 2005 Dec; 5(12):3009-14. PubMed ID: 16303017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.
    Sutherland AI; Akhtar MZ; Zilvetti M; Brockmann J; Ruse S; Fuggle SV; Sinha S; Harden P; Friend PJ
    Am J Transplant; 2014 Mar; 14(3):677-84. PubMed ID: 24612687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
    Sundberg AK; Roskopf JA; Hartmann EL; Farney AC; Rohr MS; Stratta RJ
    Transplant Proc; 2005 Mar; 37(2):1294-6. PubMed ID: 15848701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation.
    Turgeon NA; Avila JG; Cano JA; Hutchinson JJ; Badell IR; Page AJ; Adams AB; Sears MH; Bowen PH; Kirk AD; Pearson TC; Larsen CP
    Am J Transplant; 2010 Sep; 10(9):2082-91. PubMed ID: 20883542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes.
    Thai NL; Khan A; Tom K; Blisard D; Basu A; Tan HP; Marcos A; Fung JJ; Starzl TE; Shapiro R
    Transplantation; 2006 Dec; 82(12):1621-4. PubMed ID: 17198247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation.
    Shapiro R; Ellis D; Tan HP; Moritz ML; Basu A; Vats AN; Khan AS; Gray EA; Zeevi A; McFeaters C; James G; Jo Grosso M; Marcos A; Starzl TE
    J Pediatr; 2006 Jun; 148(6):813-8. PubMed ID: 16769394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab (Campath-1H) in kidney transplantation.
    Ciancio G; Burke GW
    Am J Transplant; 2008 Jan; 8(1):15-20. PubMed ID: 18093269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up.
    Tan HP; Donaldson J; Basu A; Unruh M; Randhawa P; Sharma V; Morgan C; McCauley J; Wu C; Shah N; Zeevi A; Shapiro R
    Am J Transplant; 2009 Feb; 9(2):355-66. PubMed ID: 19120078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.